<DOC>
	<DOCNO>NCT02462304</DOCNO>
	<brief_summary>Objectives : To compare efficacy monotherapy anti-Vascular Endothelial Growth Factor ( ranibizumab bevacizumab ) combine therapy anti-Vascular Endothelial Growth Factor end-point-management grid laser photocoagulation diabetic macular edema . Study design : Open-label non-randomized interventional study . Study overview : This study aim look efficacy treat diabetic macular edema ( DME ) either anti-Vascular Endothelial Growth Factor ( anti-VEGF ) monotherapy , compare combination therapy anti-VEGF End-Point-Management ( EPM ) grid laser photocoagulation , period 6 month . Various site across Asia ( Japan , South Korea , Hong Kong ) participate . Depending availability EPM laser , sit either contribute 'Anti-VEGF monotherapy ' arm , 'Combination therapy ' arm .</brief_summary>
	<brief_title>To Compare Anti-VEGF Monotherapy With Anti-VEGF EPM Grid Laser Combination Therapy Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Age ≥ 18 year CSME Diagnosis diabetes mellitus ( type 1 type 2 ) At least one eye meet study eye criterion Able willing provide inform consent prior studyrelated procedure Central foveal thickness ≥ 300 micron baseline ( SPECTRALIS Cirrus HD OCT ) LogMAR Best correct visual acuity 0.20 ( Snellen 20/30 ) 1.3 ( Snellen 20/400 ) . Willing able comply clinic visit studyrelated procedure Central Foveal Thickness OCT 300600 micron After first injection , wait ME reduce proceed laser . Exclude ME persist &gt; 500um 4week follow Macular edema consider due cause diabetic macular edema . An ocular condition present , opinion investigator , visual acuity loss would improve resolution macular edema ( e.g. , foveal atrophy , VMT , pigment epithelium abnormality , dense subfoveal hard exudate , nonretinal condition glaucoma etc ) . Substantial cataract , opinion investigator , likely affect visual acuity . Likely affect BCVA perform laser treatment . History treatment diabetic macular edema time past ( grid macular photocoagulation ) . History treatment diabetic macular edema time past 3 month ( intravitreal peribulbar corticosteroid , ranibizumab , bevacizumab , aflibercept ) . Focal laser photocoagulation perform enrol study need . 3 month gap require last laser procedure recruitment . History panretinal ( scatter ) photocoagulation ( PRP ) within 3 month prior enrollment . Anticipated need PRP study period . History major retinal surgery ( include vitrectomy , scleral buckle , glaucoma surgery , etc. ) . History YAG capsulotomy perform within 3 month . Aphakia . Intraocular pressure ≥ 25 mmHg . History openangle glaucoma ( either primary openangle glaucoma cause openangle glaucoma ; note : history angleclosure glaucoma exclusion criterion ) . Exam evidence external ocular infection , include conjunctivitis , chalazion , significant Blepharitis . Systemic A subject eligible follow exclusion criterion present : Significant renal disease , define history chronic renal failure require dialysis kidney transplant . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure , cardiovascular disease , glycemic control ) . Blood pressure &gt; 180/110 ( systolic 180 OR diastolic 110 ) . Major surgery within 28 day prior randomization major surgery plan next 6 month . Myocardial infarction , cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 6 month prior randomization . Systemic antivascular growth factor ( ranibizumab ) proVEGF treatment within 4 month . For woman childbearing potential : pregnant lactate intend become pregnant within next 12 month . Subject expect move area clinical center area cover another clinical center study . The target eye eye subject , fellow eye 's visual acuity lower 1.3 LogMAR unit . Baseline logMAR BCVA 0.05 0.5 ( Snellen ) Fellow eye BCVA 0.05 worse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetic Macula Edema</keyword>
	<keyword>End-Point-Management</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>bevacizumab</keyword>
</DOC>